Compare GDEV & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDEV | CABA |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Cyprus | United States |
| Employees | 589 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.9M | 319.6M |
| IPO Year | N/A | 2019 |
| Metric | GDEV | CABA |
|---|---|---|
| Price | $14.00 | $2.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 784.0 | ★ 2.2M |
| Earning Date | 04-06-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $5.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.60 | $0.99 |
| 52 Week High | $42.20 | $3.78 |
| Indicator | GDEV | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 46.30 |
| Support Level | $12.49 | $2.11 |
| Resistance Level | $16.62 | $3.34 |
| Average True Range (ATR) | 0.43 | 0.21 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 5.21 | 17.50 |
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.